The global Cell Therapy Raw Materials market was valued at USD 3.98 Billion in 2022 and is projected to reach USD 17.48 Billion by 2030, registering a CAGR of 23.54% for the forecast period 2023-2030.
Cell therapy raw materials play a pivotal role in the development and manufacturing of cell-based therapies, which have emerged as a promising frontier in the field of regenerative medicine and immunotherapy. These raw materials encompass a diverse range of components, including cells, culture media, growth factors, and quality control reagents, essential for the growth, expansion, and quality assurance of therapeutic cells. Ensuring the safety, efficacy, and consistency of cell-based therapies is contingent on the selection of high-quality raw materials and adherence to stringent regulatory standards like Good Manufacturing Practices (GMP). Suppliers, manufacturers, and developers of cell therapies must rigorously vet their raw material sources, maintain robust supply chains, and invest in risk mitigation strategies to guarantee the quality and reliability of their products. As the cell therapy field continues to advance, research and innovation are driving the development of more specialized and customized raw materials tailored to different therapeutic applications, making this a dynamic and evolving sector of the healthcare industry.
For instance, in July 2023, University of Buffalo (UB), was awarded $3 million NIH grant for studying immune cell therapy for tumors.
- 2022: USD 3.98 billion
- 2030: USD 17.48 billion
- CAGR (2023-2030): 23.54%
Cell Therapy Raw Materials Market Dynamics
Governments to invest in R&D of cell therapy : Governments around the world have recognized the potential of cell-based therapies to address various medical conditions and improve patient outcomes, leading to increased investments in research, development, and manufacturing in this field. Government funding has been channeled into supporting research initiatives, clinical trials, and infrastructure development, providing financial resources for academic institutions, research organizations, and biotech companies to advance cell therapy technologies. This support has not only accelerated the discovery of novel cell therapies but also fostered a more favorable environment for the production of high-quality raw materials, ensuring the safety and efficacy of these therapies.
For instance, in March 2022, UK government to invest £260 million to boost healthcare research and manufacturing. Further £60 million is allotted for supporting commercial-scale manufacturing investments by companies at leading-edge of innovation, from cell and gene therapies.
In September 2023, Agilent and Actris signed MOU for cell and gene therapy acceleration in Singapore. This partnership aims to set and install Agilent’s xcelligence real-time cell analyzer, seahorse xf technology and other cell analysis portfolio.
In July 2023, Hitachi announced its collaboration with Mass General Brigham for accelerating gene and cell therapy (GCT) to conquer intractable diseases and realize practical applications.
High costs can restrain the cell therapy raw materials market : The production of cell-based therapies necessitates a range of specialized and often costly raw materials, such as growth factors, culture media, and quality control reagents, to maintain the quality, safety, and efficacy of the final product. These expenses are particularly pronounced in the early stages of therapy development and clinical trials, where economies of scale have not yet been achieved. The high cost of raw materials can impact the affordability and accessibility of cell therapies, limiting patient access and the commercial viability of these treatments. As a result, manufacturers often seek ways to optimize their supply chains, explore alternative sourcing options, and develop more cost-effective production processes. Government support and incentives, along with technological advancements and standardization in the industry, can help address these cost challenges, making cell therapies more accessible and cost-efficient in the long term.
Supply chains struggles for manufacturers : The complex nature of cell therapies, which often involve the use of sensitive and specialized materials, necessitates a robust and reliable supply chain. the procurement of raw materials, including cells, culture media, and growth factors, can be susceptible to fluctuations in availability and quality. For example, sourcing sufficient and consistent quantities of high-quality donor cells for allogeneic therapies can be challenging. Any disruption in the supply chain can lead to production delays and affect therapy development and patient access. the rapid growth of the cell therapy industry, coupled with the increasing demand for these innovative treatments, has strained supply chains. Many manufacturers have experienced difficulties in scaling up production to meet this heightened demand. Ensuring the consistency and reliability of materials, such as culture media and quality control reagents, becomes more challenging as production volumes increase. This growth has led to a competitive marketplace, where securing the necessary raw materials and production capabilities is increasingly challenging, particularly for smaller manufacturers and startups.
Innovation & development in new cell therapies offering new opportunities for the market : Innovation in therapies are opening doors to novel treatment modalities, with the potential to address previously untreatable or poorly managed medical conditions. The advent of new cell therapies is expanding the scope of personalized medicine, as many of these treatments are tailored to individual patients, allowing for more precise and effective interventions. As new therapies emerge, there is a corresponding surge in the development of specialized raw materials, manufacturing technologies, and quality control methods. This dynamic environment fosters opportunities for companies involved in the production and supply of these materials, offering new revenue streams and market niches. Additionally, the increasing demand for skilled professionals in cell therapy research, manufacturing, and clinical management is creating job opportunities in an emerging and rapidly evolving field.
|Market Size in 2022
|USD 3.98 Billion
|Market Forecast in 2030
|USD 17.48 Billion
|Compound Annual Growth Rate (CAGR)
|Revenue (USD Million) and Volume (Kilo Tons)
|By Product, By End-Use, & By Region
|2018 - 2022
|2023 - 2030
Segment Analysis of the Cell Therapy Raw Materials Market
The cell therapy raw materials market is segmented by product, by end-use, & by region.
The media segment dominated the market in 2022 : Based on the product segment the market for cell therapy raw materials is classified into reagents & buffers, cell culture supplements, antibodies, sera, media, and others. The media segment dominated the market in 2022. Cell culture media plays crucial role in cancer treatment. With various benefits like customization and can be formulated to meet the requirements to different cell types and applications allowing researchers and manufacturers to fine-tune conditions for optimal results. High quality media to contribute to consistency and reproducibility in cell culture experiments and production of therapeutic cells are the factors contributing to segments growth. For instance, in October 2023, Kite and Epic Bio announced collaboration for developing new therapies for cancer.
The cell therapy raw materials market based on the segment end-use is classified into CROs & CMOs, biopharmaceutical & pharmaceutical companies, and others. The biopharmaceutical & pharmaceutical companies segment holding largest market share in 2022. Investments in cell therapy research, development, and commercialization have increased dramatically, which has increased demand for premium raw materials needed to produce cell treatments. These companies invest heavily in R&D aiming for new discoveries or treatments for various medical conditions, ranging from common ailments to rare diseases contributing to segments growth. For instance, in September 2023, Novo Nordisk A/S announced an investment of USD 136 million for the construction of a cell therapy manufacturing facility at Cellerator in Denmark. This facility will produce cell therapies in particularly the stem cell therapies which is used in preliminary clinical studies.
North America dominated the market in 2022 : The North America region dominated the market in 2022. The region boasts a strong foundation of research and innovation, with a high concentration of world-renowned universities, research institutions, and biotechnology hubs. Additionally, it benefits from a supportive regulatory environment, particularly in the United States, which encourages drug development and facilitates market access. A robust healthcare infrastructure, access to capital, and a large patient population for clinical trials also contribute to the region’s dominance. On the other hand, Asia-Pacific is the fastest growing region with a rapidly expanding middle class and increasing healthcare expenditure, the region represents a vast and growing market for pharmaceutical products. In addition to its large population, the Asia Pacific offers cost-effective manufacturing capabilities and a skilled workforce, attracting global pharmaceutical companies to establish production facilities and research centers.
List of the prominent players in the Cell Therapy Raw Materials Market:
- Thermo Fisher Scientific Inc.
- Roosterbio, Inc.
- Merck Kgaa
- Charles River Laboratories
- Sartorius Stedim Biotech
- Promocell Gmbh
- Stemcell Technologies
- Grifols, S.A.
Segmentation Analysis of the Cell Therapy Raw Materials Market
- Reagents & Buffers
- Cell Culture Supplements
- CROs & CMOs
- Biopharmaceutical & Pharmaceutical Companies
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Impact of the COVID-19 Pandemic on the Cell Therapy Raw Materials Market:
The COVID-19 pandemic had a significant impact on the cell therapy raw materials market in multiple ways. Firstly, with the implementation of lockdowns from various governments of various countries to avoid public gathering in order to restrict spread of virus. This resulted in shortages of labors and affected the production and transportation of raw materials, particularly those sourced internationally. This created challenges for cell therapy developers in maintaining a consistent supply of critical components, potentially delaying research and clinical trials.
The pandemic has had both negative and positive effects on the cell therapy raw materials market. However, the need for robust and adaptable supply chains in the cell therapy raw materials market. It encouraged companies to explore alternative sourcing options and invest in contingency plans to mitigate future disruptions. These experiences highlighted the significance of supply chain resilience and strategic planning in the cell therapy industry.